Nephrologie & therapeutique最新文献_第7页

COVID-19 early curative treatments in kidney transplant recipients: is it really reasonable at the Omicron era? 肾移植受者的新冠肺炎早期治疗：在奥密克戎时代真的合理吗？

Nephrologie & therapeutique Pub Date : 2023-11-02 DOI: 10.1684/ndt.2023.44

Yanis Tamzali, Alexia Lundy, Alexandre Bleibtreu, Maud Cazenave, Inna Mohammadou, Nadia Arzouk, Pierre Galichon, Stéphane Marot, Helga Junot, Benoît Barrou, Valérie Pourcher, Jérôme Tourret

{"title":"COVID-19 early curative treatments in kidney transplant recipients: is it really reasonable at the Omicron era?","authors":"Yanis Tamzali, Alexia Lundy, Alexandre Bleibtreu, Maud Cazenave, Inna Mohammadou, Nadia Arzouk, Pierre Galichon, Stéphane Marot, Helga Junot, Benoît Barrou, Valérie Pourcher, Jérôme Tourret","doi":"10.1684/ndt.2023.44","DOIUrl":"10.1684/ndt.2023.44","url":null,"abstract":"Objective: Data about efficacy and safety of the latest COVID-19 treatments as nirmatrelvir/ritonavir (n/r) or Sotrovimab is scarce in solid organ transplant recipients in the Omicron era. This study aims at describing the outcome of kidney transplant recipients (KTRs) presenting Omicron infection according to their management: n/r, sotrovimab or no specific treatment.Patients and methods: We conducted a monocentric, retrospective observational study, including KTRs diagnosed Omicron infection between January and May 1st 2022 and compared their outcome (primary outcome defined as hospital admission for COVID-19 within a month after symptoms onset) according to early COVID-19 management.Results: Forty-five patients were included: 22 treated (12 n/r, 10 sotrovimab) and 23 with no specific treatment. The groups were statistically comparable. Two patients were admitted for COVID-19: one in each group, resulting in a non-different probability of the primary outcome at on month (p=0.9). Three patients presented tacrolimus overdose including two with acute kidney injury.Conclusions: There was no difference in outcome according to early therapeutic management: n/r, sotrovimab or no specific treatment. Our study both underlines a decreased severity of Omicron COVID-19 in KTRs (probably related to vaccinal immunity and decreased virulence of Omicron) and a potential severe adverse effects with n/r.","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"19 6","pages":"491-496"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}